Skip to content

CARESTREAM Vue PACS v12.1.5 CT Perfusion Clinical Protocol

CARESTREAM Vue PACS v12.1.5 CT Perfusion Clinical Protocol

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02557282
Acronym
CTP
Enrollment
30
Registered
2015-09-23
Start date
2015-09-30
Completion date
2015-09-30
Last updated
2018-11-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ischemia

Brief summary

The purpose of this clinical study is to evaluate the CARESTREAM Vue PACS 12.1.5 Computed Tomography (CT) Perfusion (investigational device) imaging performance. Evaluation of CT Perfusion (CTP) imaging will compare CTP with the predicate device, the Olea Sphere PACS with CT Perfusion Module.

Detailed description

This study will demonstrate the imaging performance CTP by an assessment of 30 CTP de-identified patient cases collected retrospectively. The purpose of the study is to demonstrate equivalent clinical quality between the investigational and predicate devices using a radiologist evaluation of key metrics which are applicable to CTP images. The maps include the following: * Mean Transfer Time (MTT) - the time that the contrast material stays in the tissue * Cerebral Blood Volume (CBV) - the volume of blood that is in a known volume of the tissue based on the concentration of contrast material that is in the tissue over the time * Cerebral Blood Flow (CBF) - describes the flow of the blood to the affected tissue * Time To Peak (TTP) - the time that maximum enhancement is achieved at each volume of the tissue * Time to maximum of impulse response function (TMAX) The retrospective data collected for each patient will include a non-contrast head CT exam completed on the same day as CTP image, and a follow-up head CT at least 1-2 days after the initial imaging study (initial non-contrast head CT) if available. Similar performance between the investigational and predicate devices was demonstrated by the following criteria. i. Substantial equivalence of the perfusion maps between devices ii. Substantial equivalence of the core and penumbra tissues resulting from thresholds on the perfusion maps between devices iii. The clinical decision based on the exclusion or inclusion criteria for treatment is equivalent between devices

Interventions

None listed

Sponsors

Carestream Health, Inc.
Lead SponsorINDUSTRY

Study design

Observational model
CASE_ONLY
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Retrospective patient CTP cases with case maps that include the following information: MTT, CBV, CBF, TTP, and TMAX. * Initial CT exam and CT exam 1-2 days after the initial exam if available, and * Retrospective CTP case with subject/patient 18 years of age or older

Exclusion criteria

* Low quality images, or images that are not clinically acceptable for clinical diagnostic reading as determined by the Principal Investigator, * Subject less than 18 years of age

Design outcomes

Primary

MeasureTime frameDescription
To compare the diagnostic value of CTP in CARESTREAM Vue PACS (investigational device) to the Olea Sphere PACS with CT Perfusion Module (predicate device).one monthDemonstrate equivalent clinical quality between the investigational and predicate devices.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026